Alterations of mineral bone metabolism in hemodialysis patients at the Itauguá National Hospital
DOI:
https://doi.org/10.70108/nefrologiapy.2023.1.1.10Keywords:
nephrotic syndrome, podocyto- pathy, nephropathy related to type iv collagenAbstract
Introduction: Mineral and bone metabolism disorders associated to chronic kidney disease include: biochemical alterations, alterations in bone turnover, mineralization, volume, linear growth and resistance; and vascular and soft tissue calcifications. It is present in almost all dialysis patients, and have been associated with higher mortality.
Objective: To determine the prevalence of bone mineral metabolism disorders in patients with chronic kidney disease on hemodialysis Department of Nephrology of the National Hospital in the year 2021-2022. Methodology: Observational, descriptive, cross-section, al and retrospective study. Sample: 93 patients on three-weekly hemodialysis.
Results: male prevalence (56%), with an average age of 46 years, average time on dialysis of 7 years, prevalent cause of CKD: type 2 diabetes mellitus (32%), 70% of patients did not present vascular calcifications, almost all of the patients studied (85/93) met some criteria for BMD-CKD, among which the main findings were: hyperphosphatemia 53% and hyperparathyroidism.
Conclusion: A lArge number of patients present alterations in bone mineral me- tabolism with values outside the range suggested by the KDOQI guidelines, more evident for phosphorus and PTH, this reflects the existing difficulty to achieve the values suggested by the guidelines.
Downloads
Metrics
References
(1) Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A et al: Chronic kidney disease as a global public health problem: approaches and initiatives - a position state- ment from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72(3):247-259. [Pubmed]
(2) DuBose TD, Jr.: American Society of Nephrology Presidential Address 2006: chronic kidney disease as a public health threat--new strategy for a growing problem. Journal of the American Society of Nephrology: JASN 2007, 18(4):1038-1045. [Pubmed].
(3) Otero A, de FA, Gayoso P, Garcia F: Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 2010, 30(1):78-86. [Pubmed].
(4) Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003, 41(5 Suppl):11-17. [Pubmed].
(5) Soriano S, Luño J. Valoracion clínica diagnostica del enfermo con insuficiencia renal crónica. En: P. Aljama, J. Egido, S. Lamas editores. Hernando Nefrología Clínica 4ta edición. Madrid: Editorial Medica Panamericana, 2014.
(6) Abrita, R. R., Pereira, B. dos S., Fernandes, N. da S., Huaira, R. M. N. H., Bastos, M. G. 2018. Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney diseasemineral and bone disorder in 11 dialysis centers. Jornal Brasileiro de Nefrologia, 40(1), 26–34.
(7) KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017 7(1), 1–59.
(8) National Kidney Foundation. K/ DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201.
(9) Torregrosa, JV., Bover, J., Cannata Andía, J., Lorenzo, V., de Francisco, AM., Martínez, I., Rodríguez Portillo, M., Arenas, L., González Parra, E., & Caravaca, F. (2011). Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (SEN-MM). Nefrología, 31, 3–32.
(10) Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: Global dimension and perspectives. Lancet. 2013;382(9888):260-72.
(11) Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, Bommer J, Kerr PG, Tentori F, Akiba T et al: Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012, 60(1):90-101.
(12) Jin, J.-J., Zhang, S.-L., Xu, J.-S., Cui, L.-W., Zhang, H.-R., & Bai, Y.-L. (2018). Prevalence of Chronic Kidney Disease- Mineral Bone Disorder in Hemodialysis Patients in Hebei, China. Chinese Medical Journal, 131(22), 2749–2751. https://doi.org/10.4103/0366-6999.245264
(13) Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín J, Rodríguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-47.
(14) Abrita, R. R., Pereira, B. dos S., Fernandes, N. da S., Abrita, R., Huaira, R. M. N. H., Bastos, M. G., & Fernandes, N. M. da S. (2018). Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease- mineral and bone disorder in 11 dialysis centers. Jornal Brasileiro de Nefrologia, 40(1), 26–34. https://doi. org/10.1590/2175-8239-JBN-3527
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Nelly Delgado Lombardi, Marta Cazo
This work is licensed under a Creative Commons Attribution 4.0 International License.
